ZIMPERIUM, INC. – Trademark Portfolio
Entity Type: 03
ZIMPERIUM, INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ZIMPERIUM, APPCOMPARE, APPVISUALIZER, and WHITECRYPTION. The owner is based in DALLAS, TX.
4055 VALLEY VIEW
DALLAS, TX 75244
Showing of trademarks Trademarks
Trademark Classifications
ZIMPERIUM, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does ZIMPERIUM, INC. have?
ZIMPERIUM, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 4 abandoned, 2 cancelled.
What trademark classes does ZIMPERIUM, INC. file in?
ZIMPERIUM, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 45 (Legal & Security Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are ZIMPERIUM, INC.'s most well-known trademarks?
ZIMPERIUM, INC.'s registered trademark portfolio includes well-known marks such as ZIMPERIUM, APPCOMPARE, APPVISUALIZER, and WHITECRYPTION. These are among 5 currently registered trademarks in the portfolio.
What is ZIMPERIUM, INC.'s trademark registration success rate?
ZIMPERIUM, INC. has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.